Curis To Present Updated Data From TakeAim Leukemia Study At The ASCO And EHA Conferences
Data update expands AML dataset from 5 to 30 patientsLEXINGTON, Mass., May 14, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally